A detailed history of Braidwell LP transactions in Replimune Group, Inc. stock. As of the latest transaction made, Braidwell LP holds 3,070,837 shares of REPL stock, worth $33.2 Million. This represents 0.95% of its overall portfolio holdings.

Number of Shares
3,070,837
Previous 1,013,377 203.03%
Holding current value
$33.2 Million
Previous $9.12 Billion 269.02%
% of portfolio
0.95%
Previous 0.29%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$8.09 - $11.23 $16.6 Million - $23.1 Million
2,057,460 Added 203.03%
3,070,837 $33.7 Billion
Q2 2024

Aug 14, 2024

BUY
$5.01 - $9.46 $5.08 Million - $9.59 Million
1,013,377 New
1,013,377 $9.12 Billion
Q2 2023

Aug 14, 2023

BUY
$15.65 - $24.1 $6.48 Million - $9.97 Million
413,855 Added 561.81%
487,520 $11.3 Billion
Q1 2023

May 15, 2023

SELL
$17.48 - $29.09 $10.3 Million - $17.1 Million
-588,684 Reduced 88.88%
73,665 $1.3 Billion
Q4 2022

Feb 14, 2023

BUY
$17.09 - $27.91 $11.3 Million - $18.5 Million
662,349 New
662,349 $18 Billion

Others Institutions Holding REPL

About Replimune Group, Inc.


  • Ticker REPL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,306,700
  • Market Cap $533M
  • Description
  • Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...
More about REPL
Track This Portfolio

Track Braidwell LP Portfolio

Follow Braidwell LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Braidwell LP, based on Form 13F filings with the SEC.

News

Stay updated on Braidwell LP with notifications on news.